A Phase IV, Open-Label, Multi-center Study to Evaluate the Safety of Apixaban in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery
Phase of Trial: Phase IV
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Apixaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 13 May 2019 Status changed from recruiting to completed.
- 14 Sep 2017 Planned End Date changed from 27 Feb 2018 to 31 Dec 2018.
- 14 Sep 2017 Planned primary completion date changed from 26 Feb 2018 to 30 Dec 2018.